uploads/2018/02/Farxiga.png

Behind the High Growth of AZN’s Farxiga and Onglyza in 4Q17 and 2017

By

Updated

Farxiga’s revenue trends

In 4Q17, AstraZeneca’s (AZN) Farxiga reported revenues of $332.0 million, which reflected ~39.0% growth on a year-over-year (or YoY) basis and ~16.0% growth quarter-over-quarter.

In fiscal 2017, Farxiga reported revenues of $1.1 billion, which reflected ~29.0% YoY growth. Presently, Farxiga is the leading drug in the SGLT2 (sodium-glucose cotransporter 2) inhibitor class of drugs.

In 2017, in the US market, Farxiga reported revenues of $489.0 million, which is ~7.0% YoY growth. AstraZeneca’s participation in affordability programmes primarily contributed to a slight 1.0% decline of the US YoY revenues during 1H17. In 4Q17, in the US market, Farxiga generated revenues of $150.0 million, which reflected ~15.0% growth on a YoY basis.

In 2017 in Europe, Farxiga reported revenues of $242.0 million, which reflected ~29.0% growth on a YoY basis. Along with leadership position in the SGLT2 class in the European markets, Farxiga also demonstrated growth in market share in the innovative oral class of drugs.

In the marketplace, Farxiga competes with Johnson and Johnson’s (JNJ) Invokana, and Eli Lilly’s (LLY) Jardiance.

Article continues below advertisement

Onglyza’s revenue trends

In 4Q17, AstraZeneca’s Onglyza generated revenues of $180.0 million, which reflected ~21.0% growth on a YoY basis. In fiscal 2017, Onglyza reported revenues of $611.0 million, which is an ~15.0% decline on a YoY basis.

In 2017 in the emerging markets, Onglyza generated revenues of $130.0 million, which is an ~8.0% decline on a YoY basis. In 2017, Onglyza was registered in China’s National Reimbursement Drug List (or NRDL), which propelled the drug’s revenue growth in 4Q17 in China. In 4Q17 in the emerging markets, Onglyza generated revenues of $37.0 million, which is ~16.0% YoY growth.

In 2017, in Europe, Onglyza reported revenues of $104.0 million, which is an ~21.0% YoY decline.

In the diabetic care market, Onglyza, a dipeptidyl peptidase-4 (or DPP-4) inhibitor, competes with Eli Lilly’s (LLY) Tradjenta and Merck’s (MRK) Januvia.

Advertisement

More From Market Realist